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Open access under CC BY-NC-ND license.in the tumor microenvironment (eg, Toll-like recep-
tor [TLR] agonists, type I interferons, and inhibitors
of myeloid-derived suppressor cells [MDSCs]).1
Many agents are now in development within each
of these distinct classes (see article by Disis in
this supplement), and a range of new strategies is
being investigated, most notably combinations of
these agents.COMBINATION THERAPY AS FUTURE OF
IMMUNOTHERAPY
One strategy to improve the effectiveness of
immunotherapy is to look for synergistic combina-
tions. This may involve combining immunotherapy
with traditional cytotoxics such as chemotherapy or
radiation, or combining two immunotherapeutic
agents that have complementary mechanisms of
action.2 The former strategy has been employed for
more than a decade in the form of immunoconju-
gates that induce both direct and immune-mediated
cytotoxicity.3 Examples include radiolabeled anti-
CD20 monoclonal antibodies (mAbs) such as ibritu-
momab tiuxetan and tositumomab for the treatment
of B-cell lymphoma, and conjugates of mAbs with
cytotoxic agents such as gemtuzumab ozogamicin
for acute myelogenous leukemia (AML) and trastu-
zumab emtansine for human epidermal growth
factor receptor 2 (HER2)-positive breast cancer.
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toxicity must be considered. To date, this approach
has mainly been limited to co-administration of well-
characterized immune adjuvants, such as IL-2 or
granulocyte-macrophage colony-stimulating factor
(GM-CSF), together with tumor-specific mAbs,
tumor-infiltrating lymphocytes (TILs), or cancer vac-
cines, in an attempt to stimulate the recruitment
and/or activation of immune effector cells.4 More
recently, multiple examples of successful immuno-
therapy combinations have been evaluated in pre-
clinical models,1 and clinical studies have begun to
explore the safety and effectiveness of these new
combinations. Examples include combining two
vaccines to achieve a so-called “prime and boost”
effect, combining two immune checkpoint inhibi-
tors with distinct mechanisms of action, or combin-
ing an immune checkpoint inhibitor with a vaccine.
Another area of active investigation is the combina-
tion of immune checkpoint inhibitors with chemo-
therapy and targeted therapies.Combinations of Two or More
Immunotherapies
The concept behind vaccine combinations is to
first prime the immune response to tumor antigens,
and then boost the response with a second vaccine.
This approach was recently tested in patients with
metastatic pancreatic cancer, using a combination of
pancreatic GVAX (Cell Genesys, Inc, San Francisco,
CA) and CRS-207.5 Pancreatic GVAX is a polyvalent
vaccine containing irradiated, GM-CSFsecreting,
allogeneic pancreatic cancer cell lines, and is admin-
istered intradermally. CRS-207 contains live-
attenuated Listeria monocytogenes, which expresses
mesothelin and stimulates innate and adaptive
immunity. In animal models, the combination of
GVAX and CRS-207 was synergistic. In the random-
ized phase II study of this combination, low-dose
cyclophosphamide was administered prior to GVAX
to inhibit Tregs, and overall survival (OS) was signifi-
cantly improved by the combination of GVAX fol-
lowed by CRS-207 compared with GVAX alone.
Among patients who received at least three doses of
vaccine (including at least one dose of CRS-207 in the
combination arm), median OS was 9.7 months with
the combination versus 4.6 months with GVAX alone
(hazard ratio [HR] ¼ 0.44; P ¼ .007).5 Moreover, this
improvement in OS was achieved with manageable
toxicity (local reactions to GVAX and transient fevers,
rigors and lymphopenia after CRS-207). Further
follow-up and supplemental studies are needed. Addi-
tional strategies to improve the effectiveness of
therapeutic vaccines, such as combinations with Treg
depletion (using either denileukin diftitox or anti-
CD25 mAbs), homeostatic cytokines (eg, IL-7), orimmune checkpoint inhibitors, are being investi-
gated.1 For example, a phase I trial in patients with
advanced pancreatic cancer is currently testing the
combination of the CTLA-4 inhibitor, ipilimumab,
with a pancreatic tumor cell vaccine (NCT00836407).
Another approach that may have great potential is
the combination of two immune checkpoint inhib-
itors (Table 1).6–17 The success of ipilimumab for the
treatment of metastatic melanoma has spurred devel-
opment of other immune checkpoint inhibitors,
most notably anti-PD-1 and anti–programmed cell
death ligand 1 (PD-L1) mAbs. CTLA-4 inhibitors
enhance early T-cell activation in lymphatic tissues
and increase the frequency of tumor-specific T cells,
whereas inhibition of the PD-1/PD-L1 axis modulates
the T-cell effector phase to overcome T-cell anergy
in the tumor microenvironment.2,18 Thus, there is a
strong rationale for combining an anti-CTLA-4 mAb
(eg, ipilimumab or tremelimumab) with an anti-PD-1
mAb (eg, nivolumab) or anti-PD-L1 mAb
(eg, MEDI4736). One of the hallmarks of immune
checkpoint inhibitors is the durability of the objec-
tive responses. CTLA-4 blockade yields durable
responses in approximately 10% of patients with
advanced melanoma, with some patients from the
initial phase II trials of ipilimumab having remained
free of progression for more than 5 years.18,19 Mono-
clonal antibodies targeting PD-1 and PD-L1 are much
earlier in their clinical development but seem to
induce a durable response in up to one-third of
melanoma patients.20 The hope is that the combi-
nation could yield a durable response in a much
larger proportion of patients. Studies using a B16
melanoma model have demonstrated synergy
between these two classes of mAbs.21 The initial
phase I study of the combination of ipilimumab and
nivolumab, administered either concurrently or
sequentially, demonstrated a 40% objective
response rate (ORR) with concurrent administra-
tion (53% at the highest dose level tested), and a
high proportion of patients had Z80% tumor
reduction at 12 weeks; however, more than half
of patients experienced grade 3 or grade 4
immune-related adverse events (irAEs).17 These
data are very encouraging, but raise some concerns
about the potential for additive toxicity. A number
of clinical trials are currently ongoing to test
combinations of these two agents in patients with
advanced melanoma, non-small cell lung cancer
(NSCLC), renal cell carcinoma (RCC), colon cancer,
glioblastoma, and relapsed/refractory hematologic
malignancies (Table 1). Of particular interest is a
three-arm, randomized, phase III trial
(NCT01844505) that is comparing ipilimumab
and nivolumab monotherapy with the combination
of both agents as first-line therapy for advanced
melanoma. The outcome is eagerly anticipated.
Table 1. Immune Checkpoint Inhibitor Combinations Under Investigation
Drug Name Drug Target Phase Population N*
Primary
Endpoint Efﬁcacy Results Grade 3/4 AEs Status
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
Ib Advanced
melanoma
86 Safety, ORR Concurrent cohort (n = 53):16
ORR: 42% (22/53; CRs 17%)
Clinical activity: 65%
Concurrent cohort (n = 53):
Grade 3/4 treatment-related
AEs in 53%, with most
common events being ↑ lipase
(13%), ↑ AST (13%).16
Active, not recruiting
NCT01024231
Median DoR not reached
1-yr OS rate: 82%
Sequential cohort (n = 33):
Grade 3/4 treatment-related
AEs in 18%, with the most
common AE being ↑ lipase
(6%).17
2-yr OS rate: 75%
Sequential cohort (n = 33):17
ORR: 20%
Clinical activity: 43%
Nivolumab þ ipilimumab
vs ipilimumab alone
IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
II Unresectable,
untreated
advanced
melanoma
150 ORR Not available Not available Active, not recruiting
NCT01927419
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
II Advanced
melanoma
170 Safety, ORR Not available Not available Recruiting
NCT0178393811
Nivolumab þ ipilimumab
vs nivolumab alone
or ipilimumab alone
IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
III Untreated
advanced
melanoma
915 OS Not available Not available Active, not recruiting
NCT01844505
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
I Pretreated
advanced
NSCLC
160 ORR ORR ¼ 22/129 (17.1%); 1-yr
OS rate ¼ 42%; median
OS ¼ 9.6 mo; estimated
median response
duration ¼ 74 wks.8
Grade 3/4 select AEs in
6/129 pts (5%), with most
common being skin (16%),
gastrointestinal (12%), and
pulmonary (7%). Grade 3/4
pneumonitis in
3/129 (2%)8
Recruiting NCT01928394
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
I Advanced NSCLC 46 Safety ORR: 22% Grade 3/4 treatment-related
AEs in 48%7
Recruiting NCT01454102
Median DoR not reached
SD: 33%7
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
I Relapsed or
refractory
hematologic
malignancy
180 Safety and
tolerability
Not available Not available Recruiting NCT01592370
Nivolu-
mab þ ipilimumab,
sunitinib, or
pazopanib
IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
I Metastatic renal cell
carcinoma
97 Safety and
tolerability
N3+I1 (n = 21):10
ORR: 29% DoR: 4.1þ to
22.1þ wks PFS: 4.7þ to
28.1þ wks
N3+I1 (n = 21):10 Active, not recruiting
NCT01472081
N1+I3 (n = 23):10
ORR: 39% DoR: 6.1þ to
18.3þ wks PFS: 4.3 to
26.1 wks
Grade 3/4 treatment-related
AEs in 5 pts (24%)
N1+I3 (n = 23):10
Grade 3/4 treatment-related AEs in
14 pts (61%)
Most common Grade 3/4 related
AEs in both groups overall:
↑ lipase (16%), ↑ ALT (11%),
diarrhea (9%), colitis (5%),
↑ amylase (5%)
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N+S (n = 33):6
ORR: 52% PFS at
24 wks: 78%
N+S (n = 33):6
Grade 3/4 treatment-related
AEs in 73%, with most
common events being ↑ ALT
(18%), hypertension (15%),
hyponatremia (15%)
N+P (n = 20):6
ORR: 45% PFS
at 24 wks: 55%
N+P (n = 20):6
Grade 3/4 treatment-related
AEs in 60%, with most
common events being ↑ ALT/
AST (20% each),
fatigue (15%)
Nivolumab þ ipilimumab IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
II Recurrent and
advanced colon
cancer
96 ORR Not available Not available Recruiting NCT02060188
Nivolumab alone or
Nivolu-
mab þ ipilimumab vs
bevacizumab
IgG4 PD-1 mAb þ IgG1
CTLA-4 mAb
IIb Recurrent
glioblastoma
260 Safety, OS Not available Not available Recruiting
NCT0201771714
MEDI4736 þ tremelimu-
mab
IgG1ĸ PD-L1 mAb þ IgG2
CTLA-4 mAb
I Advanced solid
tumors
102 ORR, safety Not available Not available Recruiting
NCT019758319
MEDI4736 þ tremelimu-
mab
IgG1ĸ PD-L1 mAb þ IgG2
CTLA-4 mAb
Ib Advanced NSCLC 208 MTD, safety Not reported12 Safety data available for
3 subjects. Treatment-related
AEs include a grade 2
asymptomatic ↑ amylase.
No grade 3/4 DLTs12
Recruiting NCT02000947
MK-3475 þ
chemotherapy or IMT
IgG4 PD-1 mAb I/II Advanced NSCLC 320 ORR Not available Not available Recruiting NCT02039674
Ipilimu-
mab þ bavituximab
IgG1 CTLA-4 mAb þ IgG3
phosphatides serine
mAb
Ib Advanced
melanoma
24 Safety and ORR Not available Not available Not yet recruiting
NCT01984255
Ipilimumab þ lirilumab IgG1 CTLA-4 mAb þ IgG4
KIR mAb
I Advanced
melanoma,
NSCLC, CRPC
125 Safety and
tolerability
Not available Not available Recruiting
NCT0175058013
Nivolumab þ lirilumab IgG4 PD-1 mAb þ IgG4
KIR mAb
I Advanced
refractory solid
tumors
150 Safety Not available Not available Recruiting
NCT0171473915
MEDI0680 PD-1 mAb I Advanced solid
tumors
24 Safety and
tolerability
Not available Not available Recruiting NCT02013804
MEDI0680 þ MEDI4736 PD-1 mAb þ IgG1κ PD-L1
mAb
I Advanced cancers 150 Safety and
tolerability
Not available Not available Not yet recruiting
NCT02118337
BMS-986016 alone and
with nivolumab
LAG-3 mAb þ IgG4 PD-1
mAb
I Advanced solid
tumors
168 Safety and
tolerability
Not available Not available Recruiting NCT01968109
n N indicates actual enrollment for trials that have reported data and estimated enrollment for all other trials.
Abbreviations: AE, adverse event; CRPC, castration-resistant prostate cancer; CTLA-4, cytotoxic T-lymphocyte antigen-4; DoR, duration of response; IgG, immunoglobulin G; IMT,
immunotherapy; KIR, killer cell immunoglobulin-like receptor; LAG-3, lymphocyte activation gene 3; mAb, monoclonal antibody; MTD, maximum tolerated dose; N, nivolumab; N1þI3,
nivolumab 1 mg/kg þ ipilimumab 3 mg/kg; N3þI1, nivolumab 3 mg/kg þ ipilimumab 1 mg/kg; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; P,
pazopanib; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1; pts, patients; S, sunitinib; wk, week.
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B. RiniS34Immune checkpoint inhibitors also may play an
important role in the future treatment of lung
cancer.22 Ongoing studies are investigating ipilimu-
mab and nivolumab (both in combination with
platinum-based chemotherapy) in patients with
advanced lung cancer. In a phase II study in patients
with NSCLC, first-line treatment with nivolumab plus
chemotherapy yielded an ORR of 33%, and although
grade 3/4 adverse events occurred in 49% of
patients, these were largely attributed to chemo-
therapy.23 Based on these encouraging results, sev-
eral phase III trials are underway or planned,
including a trial combining ipilimumab and nivolu-
mab in advanced NSCLC. Other anti-PD-1/PD-L1
mAbs (eg, MK-3475, MPDL3280A, and MEDI4736)
are also in development, and MEDI4736 will be
studied in a phase III trial as maintenance therapy
for NSCLC (NCT02125461). Currently, there are
several ongoing early-phase trials combining
MEDI4736 with tremelimumab in NSCLC and other
solid tumors, and the combination of MK-3475 with
either chemotherapy or immunotherapy is being
evaluated in advanced NSCLC (Table 1).
In addition to PD-1 and PD-L1, several additional
molecules have been shown to suppress the immune
response in the tumor microenvironment, including
killer cell immunoglobulin-like receptor (KIR),
which is expressed on natural killer (NK) cells and
downregulates NK cell cytotoxic activity,24,25 and
LAG-3 (CD223), a CD4-related inhibitory receptor co-
expressed with PD-1 on tolerant TILs.26,27 Antibod-
ies capable of blocking KIR (lirilumab) or LAG-3
(BMS-986016) are currently in clinical development
for the treatment of advanced solid tumors either
alone or in combination with ipilimumab or nivolu-
mab (Table 1). A key to successful application of
these novel agents will be to develop biomarkers
that can identify which checkpoints are most clin-
ically relevant in any given patient.Combinations of Immunotherapy With
Targeted Agents
Immune checkpoint inhibitors and other immu-
nomodulatory therapies also are being combined
actively with a variety of other treatment modalities,
including targeted agents, chemotherapy, and radio-
therapy (RT). It has been hypothesized that combin-
ing immunotherapy with targeted agents could be
synergistic because targeted agents can promote
apoptosis of tumor cells, thereby enhancing tumor
antigen presentation without adversely effecting
immune effector cells; they also can directly modu-
late the immune response and improve immune-cell
function, essentially acting as immune-sensitizing
agents, through a variety of mechanisms.28,29
Examples of this are shown in Table 2.29 Themultitargeted tyrosine kinase inhibitors (TKIs) imati-
nib and dasatinib are prime examples of agents that
can have clinically relevant immunomodulatory
activity, which may contribute substantially to their
antitumor activity in certain settings.29,30 Recent
studies suggest that these agents suppress the activ-
ity of Tregs and enhance NK-cell activity.31–33 Ima-
tinib blocks IDO enzyme activity, thereby
suppressing Treg numbers and function, and pro-
motes dendritic cell (DC)–NK cell crosstalk,33
whereas dasatinib appears to differentially inhibit
Treg function by blocking lymphocyte-specific pro-
tein tyrosine kinase (Lck), a critical kinase involved
in T-cell receptor signaling.32 These findings have
led to preclinical studies investigating the combina-
tion of imatinib with an anti-CTLA-4 mAb and
dasatinib with an agonist anti-OX40 mAb in an effort
to further stimulate the antitumor immune response.
These combinations appear to have synergistic anti-
tumor activity in animal models.30 A similar strategy
currently in phase I testing in melanoma is the
combination of ipilimumab with vemurafenib, which
inhibits BRAFV600E. Vemurafenib has been shown to
upregulate expression of tumor-associated antigens
(eg, gp100 and MART1) on melanoma cells,34 sup-
press secretion of inhibitory cytokines (eg, IL-10) by
tumor cells, and cause tumor antigen release.29,35
The hope is that adding ipilimumab will enhance
activation and proliferation of T cells primed by
those antigens. However, preliminary results from
the phase I trial demonstrated severe hepatic toxicity
with this combination,36 and the study was halted.
The combination of immunotherapy with anti-
angiogenic agents (eg, bevacizumab, sunitinib, and
pazopanib) is also supported by a strong biologic
rationale. Bevacizumab has been shown to increase
maturation of DCs and antigen presentation, and
sunitinib can decrease the number of MDSCs and
Tregs in the tumor microenvironment (Table 2).29
Consequently, the combination of bevacizumab plus
ipilimumab is being evaluated in a phase I study in
patients with advanced melanoma (NCT00790010),
and nivolumab is being combined with sunitinib or
pazopanib in patients with metastatic RCC in the
CheckMate 016 phase I trial (NCT01472081).
Finally, antibodies against HER2 (eg, trastuzumab)
or epidermal growth factor receptor (EGFR), such as
cetuximab, form immune complexes with tumor
cells and enhance tumor antigen presentation and
expression of co-stimulatory molecules (eg, CD40,
CD80, and CD86) on DCs.37,38 Similarly, JAK2 inhib-
itors can enhance antigen presentation by DCs by
inhibiting immunosuppressive STAT3 signaling.39,40
As a result, these agents may synergize with ther-
apeutic vaccines. Two phase II trials are currently
exploring this approach, one with trastuzumab
in HER2-positive breast cancer (NCT01570036),
Table 2. Immunomodulatory Effects of Targeted Agents and Experimental Combinations with
Immunotherapy28
Agent Primary Target(s) Effect on Immune System Experimental Combinations
Imatinib Multitargeted (BCR/ABL,
PDGF, KIT, etc.)
 Inhibits IDO
 Decreases number and activity of Treg
 Promotes DC-NK cell crosstalk
Preclinical with anti-CTLA-4 mAb in GIST
Phase II with BCR-ABL vaccine in CML
Phase III with IFN-α in CML
Dasatinib Multitargeted (BCR/ABL,
Src family kinases)
 Inhibits Treg function by blocking Lck Preclinical with an agonist anti-OX40 mAb
Vemurafenib BRAFV600E  Increases expression of tumor-associated
antigens pg100, MART1, etc
 Decreases tumor secretion of
immunosuppressive cytokines (eg, IL-10)
Phase I with ipilimumab (NCT01400451)
Bevacizumab VEGF  Increases DC maturation, antigen presentation,
and T-cell activation
 Shifts DC maturation away from MDSC
phenotype
Preclinical with adoptive T-cell transfer
Phase I with ipilimumab (NCT00790010)
Phase III with IFN-α in metastatic RCC
Sunitinib/
Pazopanib
VEGFR  Inhibits STAT3 signaling
 Decreases numbers and activity of MDSCs and
Treg cells
Preclinical with adoptive T-cell transfer in
HCC and RCC models
Preclinical with anti-CD137 agonist mAb plus
IL-12 in colon cancer model
Trastuzumab HER2  Primes tumor-speciﬁc CTLs
 Boosts NK cell secretion of IFN-γ and ADCC
Preclinical with 4-1BB agonist mAb
Preclinical with anti-PD-1 mAb
Phase I with IL-12 and paclitaxel in
HER2þ breast cancer
Phase II with HER2 peptide vaccine
Cetuximab EGFR  Mediates complement ﬁxation and ADCC
 Increases MHC class I & II expression
 Increases DC priming of tumor-speciﬁc CTLs
Phase II with EGFR vaccine (NCT00305760)
JAK2 inhibitors JAK2, STAT3  Increases DC maturation, antigen presentation,
and T-cell activation
 Inhibits STAT3 signaling
 Decreases PD-L1 expression on tumor cells
Preclinical with DC vaccines
Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; CML, chronic myelogenous leukemia; CTL, cytotoxic
T lymphocyte; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; DC, dendritic cell; EGFR, epidermal growth factor receptor;
GIST, gastrointestinal stromal tumor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; IDO,
indoleamine-2,3-dioxygenase; IFN, interferon; IL, interleukin; mAb, monoclonal antibody; MHC, major histocompatibility complex; NK,
natural killer; PD-1, programmed cell death 1; PDGF, platelet-derived growth factor; PD-L1, programmed cell death ligand 1; RCC, renal
cell carcinoma; Treg, regulatory T cell; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Future approaches in immunotherapy S35and the other with cetuximab in pancreatic can-
cer (NCT00305760). Most other combinations of
immunotherapy with targeted agents are still in
preclinical testing.Combinations of Immunotherapy With
Radiotherapy or Chemotherapy
Radiation-induced damage to tumor cells can
facilitate release of tumor-associated antigens and
high mobility group box 1 (HMGB1) protein, which
binds to TLR4 and serves as a “danger signal” that
attracts immune effector cells to the tumormicroenvironment.2,41,42 Radiation also makes
tumor cells more susceptible to immune-mediated
killing, in part via increased expression of major
histocompatibility complex (MHC) class I and death
receptors (eg, FAS).41 In fact, the available evidence
suggests that an intact immune system may be
critical for RT to exert its full antitumor effect.43
Early studies showed that combining RT with a
therapeutic vaccine resulted in tumor-specific
immune responses in the majority of patients.44,45
More recently, studies in a mouse model demon-
strated that an anti-PD-L1 mAb enhanced the efficacy
of RT through a cytotoxic T lymphocyte (CTL)-
B. RiniS36dependent mechanism, and the combination synerg-
istically reduced the number of tumor-infiltrating
MDSCs.46 Currently, a randomized phase II study in
patients with metastatic melanoma is comparing RT
plus ipilimumab with ipilimumab monotherapy
(NCT01689974). A critical issue that must be
addressed with this strategy is the optimal timing
of RT relative to administration of immunotherapy.43
The combination of immunotherapy with chemo-
therapy has long been considered to be antagonistic
because chemotherapy is often myelosuppressive
and could potentially deplete immune effector cells.
However, mounting evidence suggests that some
chemotherapy agents, such as cyclophosphamide
(depending on the dose and timing of administra-
tion), may improve antitumor immunity through a
variety of mechanisms including depletion of Tregs,
enhanced activation and proliferation of T cells and
B cells, infiltration of tumor-specific lymphocytes
into the tumor microenvironment, and activation of
myeloid DCs that secrete more IL-12 and less
IL-10.2,47–50 Early studies demonstrated that low-
doses of cyclophosphamide could augment the
immune response to therapeutic vaccines,51,52 and
an animal model demonstrated strong additive
effects in combination with an allogeneic tumor-
cell vaccine engineered to secrete GM-CSF.53 This
strategy was recently tested with a murine version of
prostate GVAX. Administration of low-dose cyclo-
phosphamide 1 day prior to the vaccine appeared to
overcome T-cell tolerance and resulted in prolifer-
ation of tumor-specific CTLs.54 In this model, the
dose and timing of cyclophosphamide was critical.
Immunomodulation was only achieved with doses
of cyclophosphamide that did not deplete T cells.
This is now being tested clinically with breast
GVAX, and early results suggest that a cyclophos-
phamide dose of approximately 200 mg/m2 enhan-
ces the immune response, whereas higher doses
are immunosuppressive.2NOVEL IMMUNOTHERAPY STRATEGIES
Some of the newest approaches to immunother-
apy are adoptive transfer of engineered T cells and
oncolytic viruses. These are still in very early phases
of development but appear to hold great promise.55
Similar to the way a patient’s autologous DCs have
been manipulated to express tumor antigens or
secrete pro-inflammatory cytokines, autologous
T cells are being genetically engineered to express
chimeric antigen receptors (CARs) that typically
consist of an mAb fragment fused to the T-cell
receptor signaling domain.56 The antibody portion
of the molecule can recognize a tumor antigen
without the need for self human leukocyte antigen
(HLA), and that induces a signal to activate the T cell.This approach has many advantages, most impor-
tantly HLA-independent antigen recognition. Early
results were disappointing, but second-generation
chimeric antigen receptor T (CAR-T) cells that
incorporated co-stimulatory signaling domains (eg,
CD28, 4-1BB, or OX-40) have proven to be effec-
tive.57,58 CAR-T cells have been investigated recently
in several pilot studies in lymphoma.56,59,60 In two
studies conducted in patients with chronic and acute
lymphocytic leukemia who received conditioning
chemotherapy (to deplete Tregs) followed by autol-
ogous CAR-T cells engineered to recognize CD19,
the transferred CAR-T cells expanded more than
1,000-fold in vivo and persisted for more than
6 months.61,62 More importantly several patients
achieved durable complete or partial responses.
However, adoptive transfer of CAR-T cells can also
cause severe toxicity due to cytokine release syn-
drome. Both autologous and allogeneic anti-CD19
CAR-T cells are now being investigated in more than
a dozen clinical trials.56
Use of oncolytic viruses as anticancer agents is an
area of active clinical research. An oncolytic virus
can selectively infect, replicate in, and kill tumor
cells, either naturally or through genetic engineer-
ing, while causing limited or no damage to normal
cells.4,63 Targeting of the virus to tumor cells and/or
selective replication in tumor cells is typically engi-
neered into recombinant viruses. Clinical trials using
a recombinant oncolytic virus were conducted
approximately 20 years ago.64,65 Since then, several
viruses exhibiting oncolytic activity have been iden-
tified and studied to determine their potential as
anticancer agents.4,55 Examples include herpes sim-
plex virus (HSV), adenovirus, pox virus, and measles
virus, which naturally infect humans, as well as
several animal viruses (eg, vesicular stomatitis virus,
Newcastle disease virus, and myxoma virus) that can
be genetically modified to infect human cells. The
first oncolytic virus was approved in China in 2005
for treating nasopharyngeal cancer (in combination
with chemotherapy)66, and several are being tested
in phase III clinical trials in the United States.67
Infection and lysis of tumor cells by an oncolytic
virus can stimulate a robust antitumor immune
response through a variety of mechanisms, including
release of tumor antigens, proinflammatory cyto-
kines, and danger signals such as HMGB1.4,63 Onco-
lytic viruses also can be engineered to direct the
infected tumor cells to produce pro-inflammatory
cytokines such as GM-CSF. For example, talimogene
laherparevec (T-VEC) is a recombinant oncolytic
HSV that produces GM-CSF and has demonstrated
good clinical activity after injection directly into
metastatic melanoma lesions. In a phase II trial, it
produced a 26% response rate against systemic
disease, following local injection into accessible
Future approaches in immunotherapy S37tumors.68 A pivotal phase III trial (OPTiM) of T-VEC
has been completed in melanoma.69 In 436 patients
with unresectable stage IIIB-IV melanoma, T-VEC
yielded a 26.4% ORR (10.8% complete response
[CR]) compared with 5.7% ORR (0.7% CR) in
patients treated with GM-CSF alone.69 Pexastimo-
gene devacirepvec (Pexa-Vec) is an oncolytic
poxvirus that also produces GM-CSF. It has been
tested in several phase I/II clinical trials and has
demonstrated promising activity in patients with
hepatocellular carcinoma.70–75FORWARD LOOK AT THE ROLE OF
IMMUNOTHERAPY
Over the next 5 to 10 years, the focus of clinical
research will be to identify and assess new combi-
nations with synergistic antitumor activity and
reduced toxicity. If the ultimate goal of cancer
immunotherapy is to achieve durable tumor erad-
ication with minimal toxicity, many obstacles and
challenges lie ahead before that promise can be
realized. Identification of appropriate tumor antigens
for development of targeted immunotherapies is a
major challenge. The ideal tumor antigen is truly
tumor specific and essential for tumor cell growth
and survival, but this is often different for each
individual tumor.55 Most mAbs and CARs target
tumor-associated cell surface antigens, but this can
lead to destruction of normal cells (eg, CD20 or
CD19-positive B cells) and selection of tumor var-
iants (through immunoediting) that no longer
express that antigen. To reduce the effect of immu-
noediting, the tumor antigen being targeted must be
essential for tumor survival. As effective immuno-
therapies become more widely available and inte-
grated into routine clinical practice outside of a few
specialized cancer centers, it also will be important
to identify biomarkers to predict response to immu-
notherapy and identify those patients who are most
likely to benefit. For example, selection of PD-L1-
positive tumors for treatment with a PD-1 or PD-L1
inhibitor appears to be a rational strategy, but a
reliable predictive biomarker for response to ipili-
mumab has been elusive.18 Another challenge is
maximizing the number of patients who achieve a
durable benefit from immunotherapy. The hope is
that combining CTLA-4 inhibitors with PD-1/PD-L1
inhibitors may move us closer to achieving that goal,
and combinations of immune checkpoint inhibitors
with targeted agents (eg, inhibitors of the BRAF/MEK
pathway in melanoma) could provide even greater
benefit, but at what cost in terms of toxicity? A final
challenge may be “dialing in” the amount of check-
point inhibition needed for a particular patient and a
given time point in disease to optimize the balance
between efficacy and toxicity.The early success of adoptive T-cell therapy for
melanoma and leukemia provides a glimpse of what
immunotherapy is capable of, but the obstacles are
overcoming tumor-induced immune suppression
and making this technology available to a broader
patient population. Perhaps CAR-T cells are the
answer, and early evidence suggests that combining
them with co-stimulatory molecules, mitogenic cyto-
kines, or immune checkpoint inhibitors may be the
secret to supercharging their antitumor potential.
Therapeutic vaccines for advanced cancer also have
new life, and new combinations of cancer vaccines
with a variety of immunomodulatory agents are
actively being investigated. However, successful
development of novel vaccine strategies and integra-
tion of those strategies into routine clinical practice
still face many challenges related to identification of
appropriate tumor antigens, overcoming immune
suppression, predictive biomarkers, and patient
selection.76,77CONCLUSIONS
Advances in our understanding of the mecha-
nisms of immune regulation and the complex inter-
actions between tumor cells and the immune system
have provided a solid foundation for the develop-
ment of combinatorial approaches and have inspired
novel immunotherapy strategies. However, much
work remains to be done to refine those strategies
and integrate them into routine clinical practice. The
recent success of immune checkpoint inhibitors and
therapeutic vaccines has sparked a renaissance in
immunotherapy, and these agents are now being
combined with a wide array of other immunothera-
pies and with targeted agents, radiotherapy, and
chemotherapy in the hope of achieving synergistic
antitumor activity. The key to the long-term success
of cancer immunotherapy is to identify optimal
tumor antigens/targets, develop predictive bio-
markers, and overcome issues with toxicity.Acknowledgments
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